International Liver Congress

International Liver Congress

May 05, 2015
1 min read

Oral DAAs effective for HIV/HCV patients

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

New all-oral, direct-acting antiviral agents were well tolerated and showed encouraging signs of virological efficacy in a study of cirrhotic patients coinfected with HIV and hepatitis C virus, according to research presented at the 2015 International Liver Congress.

“Cirrhotic HIV-HCV coinfected patients have long been considered as difficult-to-treat patients with a high mortality rate,” Philippe Sogni, MD, of the Université Paris Descartes, and colleagues wrote. “Real-life efficacy and tolerance data with sofosbuvir-based combinations in cirrhotic HIV-coninfected patients are scarce and urgently needed.”

The ANRS CO13 HEPAVIH cohort study included 106 patients (median age, 54 years; 80% men) who initiated a Sovaldi (sofosbuvir, Gilead Sciences)-based regimen between 2014 and 2015. Of these, 104 were on continuous ART. Twenty-eight percent were treatment-naive, 57% had experienced treatment failure with pegylated-interferon plus ribavirin (PR), and 11% had experienced treatment failure with PR plus a first-generation protease inhibitor. Thirty-two percent of participants had HCV genotype 1a, 12% had genotype 1b, 4% had genotype 2, 19% had genotype 3, and 23% had genotype 4.

Four treatment regimens were used:

  • sofosbuvir plus ribavirin (n =22);
  • sofosbuvir plus Daklinza (daclatasvir, Bristol-Myers Squibb), with or without ribavirin (n = 75);
  • Harvoni (ledipasvir/sofosbuvir, Gilead Sciences; n = 3); and
  • sofosbuvir plus Olysio (simeprevir, Janssen Therapeutics; n = 6).

Virologic response was observed in 52% of patients at week 4 and 100% at the end of treatment. SVR4 and SVR12 were 100% and 93%, respectively, for patients reaching this endpoint, the researchers said.

Adverse events, including anemia (36%), asthenia (14%), digestive problems (5%) and other complications (45%), were reported in 22 patients. Ribavirin was stopped in three patients and dose-adjusted in nine.

During treatment and posttreatment periods, clinical events in relation with cirrhosis were reported in 8% of patients — including hepatocellular carcinoma in two cases and decompensation in five cases — and with HIV in 4% of the patients. – by David Jwanier

Sogni P, et al. Abstract LP20. Presented at: International Liver Congress; April 22-26, 2015; Vienna.

Disclosure: Sogni reports no relevant financial disclosures.